Medicare's New $50 Obesity Drug Pilot Opens Doors for Millions of Seniors

A Historic First for Medicare Coverage

For the first time in the program's history, Medicare is helping pay for drugs prescribed solely to treat obesity. The new program marks the first time Medicare will help pay for drugs prescribed solely for obesity, rather than limiting coverage to people taking GLP-1s for conditions such as diabetes or cardiovascular disease. Starting today, July 1, that barrier has officially come down — at least temporarily.

The Medicare GLP-1 Bridge is a temporary pilot program that allows eligible Medicare recipients to get blockbuster anti-obesity medications like Wegovy and Zepbound for $50 a month. That's a dramatic shift for patients who have been paying far more out of pocket. Even with discounts, current cash prices typically range from $149 to $699 per month.

Who Qualifies and Which Drugs Are Covered

The pilot program offers coverage for the following GLP-1 medications approved for weight loss: the pill and injectable formulations of Wegovy, the KwikPen formulation of Zepbound, and the Foundayo pill. These drugs, made by Novo Nordisk and Eli Lilly, have become household names in recent years for their remarkable effectiveness.

To get access to these weight-loss medications, you must be enrolled in a Medicare Part D plan, which covers prescription drugs. After that, eligibility is based mainly on body weight and health status. People will qualify if they have a body mass index of 27 or higher and have a condition such as heart disease or prediabetes, among others. People with BMIs of 35 or higher automatically qualify. Roughly 3.8 million Medicare beneficiaries are now eligible under these criteria. Once a request gets a final sign-off, patients will pay the flat $50 copayment at the pharmacy when they pick up the prescription.

How the Program Works Around a Decades-Old Law

Medicare didn't simply change the rules — it found a creative workaround. Under federal law, Medicare Part D plans cannot cover medications prescribed for weight loss, among several other "excluded" categories of drugs and indications. Congress enacted that ban in 2003, citing safety concerns with earlier weight-loss medications and potentially high program costs.

As KFF's Juliette Cubanski explained, "Medicare is not changing the law right now. What it's doing is taking advantage of a specific section of the law that gives the federal government the ability to stand up a temporary program." CMS will provide Part D beneficiaries with coverage of select GLP-1s for obesity from July 1, 2026, to December 31, 2027, through the Medicare GLP-1 Bridge, which is a short-term demonstration established using special research authority. Officials estimate the pilot will cost the federal government between $2.5 billion and $4.4 billion annually.

What Comes Next — and Why It Matters

The health stakes behind this program are significant. The U.S. adult obesity rate has nearly tripled since the 1960s to roughly 40%, increasing the risk of heart disease, diabetes, and other chronic conditions. GLP-1s, a class of drugs used to treat type 2 diabetes, obesity, cardiovascular disease, and other conditions, have exploded in popularity in recent years due to their demonstrated effectiveness. Clinical trials show these medications can help patients lose an average of 15% to 20% of their body weight over approximately 15 to 17 months.

But the program's future is anything but certain. After that 18-month trial, patients could lose access to Medicare coverage for GLP-1s used for weight loss unless the Centers for Medicare & Medicaid Services issues an extension or Congress changes the law. As Cubanski put it, "In the short term, we have this temporary program, and then no clear path forward yet as to what will happen at the end of 2027." For millions of seniors finally within reach of these life-changing medications, that uncertainty looms large — making the political and legislative battles ahead just as important as the medical ones.